Effect of quercetin on the echocardiographic parameters of left ventricular diastolic function in patients with gout and essential hypertension.

OBJECTIVE

Introduction: Gout is associated closely with an increased risk of cardiovascular (CV) events including heart failure. The aim: Improvement of treating patients with gout and essential hypertension (EH) by applying course therapy of quercetin of the echocardiographic parameters of the left ventricular diastolic function.

PATIENTS AND METHODS

Materials and methods: 84 male patients with gout and EH. The main group consists of 43 patients who have performed treatment with quercetin and a comparative group of 41 patients who were performed treatment without quercetin.

RESULTS

Results: In patients with gout in combination with EH, the addition of quercetin to antihypertensive and urate-lowering treatment have a protective effect on cardiac diastolic function (the baseline-adjusted changes during 12 months were significantly lower in the quercetin group than in the comparative group for E/e' (-0,41± 0,01 vs. -0,08 ± 0,01, p = 0,001) and LV mass index, g/m2 (-3,28 ± 0,02 vs. -2,04 ± 0,03, p = 0,02). Also this combination contributed to faster and more pronounced achievement of the target level of uric acid (reduction by 33,7%), normalize renal function (the rate of glomerular filtration, ml/min/1,73 m2 level increase by 13,3%) and also had a cumulative antihypertensive effect (reduction of systolic blood pressure by 5,5% and diastolic blood pressure by 3,6%) without increasing the dose or adding new antihypertensive drugs.

CONCLUSION

Conclusion: adding quercetin to antihypertensive and urate-lowering regimens for 12 months in patients with gout and EH improve echocardiographic parameter of diastolic function left ventricular, purine metabolism, renal function and additional normalize blood pressure.